<DOC>
	<DOCNO>NCT01907828</DOCNO>
	<brief_summary>The purpose post market clinical investigation complete preliminary evaluation whether concomitant renal denervation EnligHTN™ Renal Denervation System cardiac ablation result improve outcome compare ablation alone patient uncontrolled hypertension treat Atrial Fibrillation</brief_summary>
	<brief_title>A Feasibility Study Evaluate Effect Concomitant Renal Denervation Cardiac Ablation AF Recurrence</brief_title>
	<detailed_description>This post market , prospective , multicenter , 2:1 randomize study EnligHTN™ Renal Denervation System conjunction atrial fibrillation ablation . Up one hundred subject paroxysmal persistent atrial fibrillation uncontrolled hypertension enrol study . All subject undergo cardiac ablation treatment atrial fibrillation . Per 2:1 randomization , minimum 50 2/3 total patient cohort also undergo renal artery ablation . Subjects followed year ( 2 ) year post procedure .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Subject ≥ 18 year age time consent Subject must able willing provide write informed consent Subject must able willing comply require followup schedule Subject candidate catheter ablation treatment paroxysmal persistent atrial fibrillation per hospital standard care Subject office Systolic Blood Pressure ≥ 140 mmHg baseline visit Subject daytime mean Systolic Ambulatory Blood Pressure &gt; 135 mmHg within 90 day prior procedure Subject establish hypertension ( diagnosed ≥12 month prior baseline ) take &gt; 3 antihypertensive medication , include 1 diuretic Subject stable unchanged antihypertensive medication regimen minimum 4 week prior ablation procedure Subject long stand atrial fibrillation Subject previous ablation atrial fibrillation Subject previous renal denervation procedure Subject CABG procedure within last 180 day ( six month ) Subject leave atrial thrombus Subject contraindication anticoagulation ( i.e . heparin warfarin ) Subject unstable angina Subject myocardial infarction within previous two month Subject leave ventricular ejection fraction ( LVEF ) &lt; 40 % determined preprocedure TTE Subject significant renovascular abnormality renal artery stenosis &gt; 30 % Subject undergone prior renal angioplasty , renal denervation , indwell renal stent , and/or abdominal aortic stent graft Subject hemodynamically significant valvular heart disease determine study investigator Subject life expectancy le 12 month , determine study investigator Subject participate another clinical study potential impact his/her hypertension atrial fibrillation management ( pharmaceutical/device/homeopathic ) Subject pregnant , nursing , childbearing potential use adequate contraceptive method Subject active systemic infection Subject renal artery &lt; 4 mm diameter Subject estimate GFR &lt; 45 mL/min per 1.73 m2 use Modification Diet Renal Disease ( MDRD ) formula Subject renal transplant await renal transplant Subject blood clot bleed abnormality Subject secondary arterial hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>